VEGFA and neoplasm: Niu et al. showed that combining a novel anti-TGF-β/VEGF bispecific antibody Y332D with PD-1 blockade increased the density and function of tumour-infiltrating lymphocytes, showing a stronger anti-tumour effect [40].